TP53 and cancer: Since PiHL is amplified in cancer cells and can increase MDM2 activity, targeting PiHL as well as MDM2 to reactivate p53 is a potential therapeutic strategy to enhance chemosensitivity in CRC, especially in tumors with PiHL overexpression.